• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Plaque Psoriasis Treatment is Launched

News
Article

Wynzora is a cream-based, fixed dose combination of calcipotriene and betamethasone for topical treatment of psoriasis.

EPI Health and MC2 Therapeutics have announced the commercial availability in the United States of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for the topical treatment of plaque psoriasis in adults 18 years of age or older.

Wynzora is a cream-based, fixed-dose combination of calcipotriene and betamethasone dipropionate. It uses the PAD Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a aqueous formulation and works to clear plaques without the messiness of conventional formulations.

“Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment of plaque psoriasis, with proven efficacy, safety and tolerability. Until now they could not be combined into an aqueous cream, which is less greasy and more user-friendly than other formulations,” John Koo, M.D., professor of dermatology at University of California San Francisco medical center and co-director, UCSF Psoriasis Treatment Center, said in a statement.

According to the National Psoriasis Foundation, psoriasis affects more than 3% of the U.S. adult population, or 7.5 million people. One in three of these will develop psoriatic arthritis, a chronic, inflammatory disease of the joints and where tendons and ligaments connect to bone.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.